Exploring a new treatment approach for Huntington's disease by modifying genetic sequences.
Therapeutic Potential of Base Editing Strategies to Convert CAG to CAA in Huntington's Disease
This study is exploring a new way to change a specific gene linked to Huntington's disease, hoping to slow down symptoms and help people with the condition feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10994073 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic approach using base editing to convert a specific genetic sequence (CAG) associated with Huntington's disease into a different sequence (CAA). By targeting the genetic cause of the disease, the researchers aim to delay the onset of symptoms and improve patient outcomes. The study utilizes insights gained from human observations and genetic analysis to develop strategies that could potentially suppress the progression of the disease. Patients with Huntington's disease may benefit from this innovative approach that seeks to address the underlying genetic factors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease, particularly those with specific genetic profiles related to CAG repeat expansions.
Not a fit: Patients without Huntington's disease or those with different genetic mutations unrelated to CAG repeats may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that delays the onset of Huntington's disease symptoms.
How similar studies have performed: Previous research has shown promise in genetic editing approaches for other conditions, suggesting potential success for this novel strategy in Huntington's disease.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Lee, Jong-Min — Massachusetts General Hospital
- Study coordinator: Lee, Jong-Min
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.